Combined anti-MET/EGFR treatment results in complete tumor regression and prevents resistance onset in a MET-amplified gastroesophageal xenopatient cohort. (July 2016) - Giordano, S.; Apicella, M.; Migliore, C.; Capeloa, T.; Menegon, S.; Cargnelutti, M.; Sapino, A.; Cassoni, P.; Marsoni, S.; Corso, S.